The FDA has approved secukinumab (Cosentyx) for adults with polymyalgia rheumatica who respond poorly to corticosteroids or cannot tolerate a steroid taper, Novartis announced Nov. 17, 2026. In the pivotal trial, 40.5% of patients reached sustained remission, double the 20.5% on placebo.
It is the first IL-17 blocker approved for the disease, Novartis said, and the second biologic after sarilumab (Kevzara), an IL-6 receptor blocker approved in February 2023. Novartis estimates about 966,000 Americans live with polymyalgia rheumatica (PMR) and that up to 40% relapse in the first year. For residents, that means a second steroid-sparing option for the older patient who flares every time prednisone comes down.
Twice the remission rate on the same 24-week steroid taper
The approval rests on REPLENISH, a phase 3, double-blind trial that randomly assigned 381 patients with recently relapsed PMR to secukinumab 300 mg, secukinumab 150 mg or placebo for 52 weeks, according to the New England Journal of Medicine report. Every group also followed the same 24-week prednisone taper.
Sustained remission meant no PMR signs or symptoms, and no new giant-cell arteritis diagnosis needing escape treatment, from week 12 through week 52. The NEJM paper reported it in 41.2% of the 300 mg group, 40.6% of the 150 mg group and 20.4% on placebo. The figures in Novartis's approval release, 40.5% vs 20.5%, differ only slightly.
“For too long, treatment options beyond glucocorticoids have been limited,” said John Stone of Massachusetts General Hospital, the trial's global principal investigator, in the Novartis release.
The higher dose added almost nothing, and the U.S. approval covers 150 mg. The European Union, where Novartis announced PMR approval on Oct. 21, 2026, allows doctors to raise the maintenance dose to 300 mg depending on response, Novartis said.
The fine print: about 1 mg of prednisone a day, and a fungal signal
The mean adjusted yearly glucocorticoid dose was 1,683.2 mg on 150 mg of secukinumab vs 2,093.0 mg on placebo, per NEJM. That is about 410 mg less per year, roughly 1.1 mg a day, because both arms were built around the same taper. The bigger win was staying in remission, not a dramatic cut in steroid.
Other limits worth knowing before you quote the trial:
- Most patients still did not reach sustained remission: about three in five on the approved dose.
- It studied relapsed disease, not new diagnoses. Glucocorticoids remain the first-line treatment, the NEJM authors write.
- Industry funding: Novartis funded REPLENISH, and at least nine of the listed authors have Novartis affiliations.
Serious adverse events occurred in 15.9% of patients on 150 mg and 14.2% on placebo. Hypersensitivity reactions (14% vs 9%) and urinary tract infections (13% vs 7%) were more common on the drug, and Novartis reported one fatal case of cryptococcal meningitis in a treated patient. NEJM also lists nasopharyngitis, fungal infections and back pain as more frequent with secukinumab.
What to remember for boards and rounds
- Same niche, two cytokines. Both biologics carry the same label wording: adults with an inadequate response to corticosteroids or who cannot tolerate a taper. Sarilumab blocks the IL-6 receptor; secukinumab is a fully human antibody against IL-17A.
- The Step 1 link to the fungal signal. Th17 cells and IL-17 are central to skin and mucosal defense against Candida, according to a 2023 review. Patients with hyper-IgE syndrome (impaired Th17 responses) or APECED (autoantibodies against IL-17A and IL-22) are prone to chronic Candida infections of skin and mucosa, a 2011 review explains. The fungal infections seen with secukinumab fit that biology.
- Do not compare the two trials head to head. In SAPHYR, 28% on sarilumab vs 10% on placebo reached sustained remission, but sarilumab patients tapered steroids over 14 weeks while placebo patients tapered over 52, Regeneron reported. REPLENISH gave every arm a 24-week taper. Different designs, no direct comparison.
- Watch for giant-cell arteritis. REPLENISH counted a new giant-cell arteritis diagnosis as treatment failure, and EULAR covers PMR and large-vessel vasculitis in one set of recommendations.
Practice-style reviews are in MedRise Shelf Prep, and our last FDA story covered obinutuzumab for membranous nephropathy. More resources are on the students and residents pages.
What to watch next
Reviews are under way in Japan and other countries, Novartis said. Guideline placement is open: the literature review behind the 2025 EULAR recommendations ran its search on Dec. 31, 2024, before REPLENISH was published. No head-to-head trial of IL-6 vs IL-17 blockade has been reported, and a 2026 review called such trials necessary. The approval release does not mention price.
PMR now has two biologics aimed at two different cytokines. For the patient who flares on every taper, the open question is which to try first, and no trial has answered it yet.
Sources: Novartis, FDA approval release (Nov. 17, 2026); Stone JH et al., Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica, NEJM 2026; Novartis, European Commission approval (Oct. 21, 2026); Regeneron, Kevzara approval for PMR (Feb. 28, 2023); Tangye SG, Puel A, J Allergy Clin Immunol Pract 2023; Hanna S, Etzioni A, J Allergy Clin Immunol 2011; Dey M et al., EULAR Rheumatology Open 2026; Manzo C, Medicines (Basel) 2026.
MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.
